Vanderbilt University has synthesized muscarinic M4 receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia and sleep ...

Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, No. 23 (June 8, 2021), pp. 1-12 (12 pages) The construction and maturation of the postsynaptic apparatus are ...

Cerevel Therapeutics Inc. has identified compounds acting as muscarinic M4 receptor agonists reported be useful for the treatment of pain, sleep disorders, schizophrenia, substance abuse and ...

Please provide your email address to receive an email when new articles are posted on . Cobenfy is the first antipsychotic medication to treat schizophrenia by targeting cholinergic receptors. The ...

Neurocrine Biosciences looks meaningfully undervalued, with ongoing growth from Ingrezza, a strong launch for Crenessity, and a promising pipeline. NBIX is looking to grow Ingrezza's market share with ...

The US Food and Drug Administration (FDA) has approved Cobenfy (Bristol Myers Squibb), a first-in-class antipsychotic approved for schizophrenia. The drug targets cholinergic receptors as opposed to ...